MedPath

Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults

Not Applicable
Recruiting
Conditions
Geriatric Disease
Drug-drug Interactions
Interventions
Device: Synapse platform
Registration Number
NCT04710615
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.

Detailed Description

The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.

The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.

More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:

* Indications, contraindications, dosage and adverse effects of drugs.

* STOPP criteria.

* START criteria.

* Associations at risk for drug-drug interactions.

Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.

This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.

Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Assistance deviceSynapse platformWith prescription assistance device: During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline).
Primary Outcome Measures
NameTimeMethod
Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription.Month 6

Proportion of patients with decrease in STOPP criteria number between initial prescription and exist prescription.

Secondary Outcome Measures
NameTimeMethod
Number of patients with decrease if active pharmaceutical ingredientsMonth 6

Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription

Number of STOPP criteriaMonth 6

Difference in the number of STOPP criteria between initial and discharge prescription

Number of START criteriaMonth 6

Difference in the number of START criteria between initial and discharge prescription.

number of patients with decrease in contraindicated drug-drug interactionMonth 6

Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription

Number of patients with increase in START criteria number between initial prescription and exist prescription.Month 6

Proportion of patients with increase in START criteria number between initial prescription and exist prescription.

Number of connections per week on Synapse platform by geriatriciansMonth 6

Number of connections per week on Synapse platform by geriatricians

Trial Locations

Locations (4)

CHU de Bordeaux

🇫🇷

Bordeaux, France

CHU de Bordeaux, Hôpital Pellegrin

🇫🇷

Bordeaux, France

CHU de Bordeaux, Hôpital Xavier Arnozan

🇫🇷

Pessac, France

Centre Hospitalier de Libourne - Pôle Gériatrie

🇫🇷

Libourne, France

© Copyright 2025. All Rights Reserved by MedPath